SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dick's Sporting Goods, Inc. engages in the retailing of an extensive assortment of authentic sports equipment, apparel, footwear, and accessories. It also offers its products both online and through mobile applications. The company was founded by Richard T. Stack in 1948 and is headquartered in Coraopolis, PA.

Dicks Sporting Goods, Inc.

DKS is plummeting after its Q2 earnings miss and full-year guidance cut, with the market heavily punishing the sporting goods retailer. Traders are actively debating whether the selloff is an overreaction or the start of a deeper decline, fueled by concerns over weakening consumer spending and the drag from its Foot Locker acquisition.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

GRRR is trending due to a sharp post-earnings selloff despite strong revenue growth and raised guidance, with the community fiercely debating whether the drop is an overreaction to accounting losses or a justified response to weak margins and potential dilution.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical minerals/rare earths are ripping on U.S. mining and supply-chain policy momentum, and CRML is catching a strong short-squeeze bid as traders point to CEO media appearances, Tanbreez development progress, and the European Lithium merger as catalysts. Community talk is split between bullish strategic-asset/squeeze narratives and persistent criticism of management, flawed valuation reports, and dilution concerns.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

LULU is trending as traders dissect Michael Burry's bullish call (calling it 'screaming cheap' and adding to his position) alongside expectations of a major EPS boost from tariff refunds and the incoming new CEO. Bulls point to insider buying and a short squeeze potential, while bears highlight analyst downgrades and tariff risks, fueling intense two-sided debate.

Greenland Mines Ltd. engages in the provision of new therapies to treat neurodegenerative diseases. It offers cell and gene therapy. The company was founded by Joseph Sinkule on August 2, 2004 and is headquartered in Charlotte, NC.

Greenland Mines Ltd.

GRML is trending on a post-reverse-split surge with a razor-thin float, as traders hype a rare earth project valuation and possible short squeeze while skeptics warn of imminent dilution from a fresh ATM offering.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

The stock is surging on a powerful combination of a heavily shorted, tightly held float and the approaching September topline data for NXC-201 in AL amyloidosis, with the community pointing to rising institutional ownership and a potential short squeeze as the story builds.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is plunging to fresh multi-year lows as the athletic sector reels from Dick's Sporting Goods' earnings miss and guidance cut, sparking intense debate about a broken brand, 'go woke go broke' narratives, and whether this is a generational bottom or a value trap.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending as investors weigh its strategic acquisition of Claros, which aims to complete its grid-to-GPU power stack and significantly expand its addressable market against ongoing concerns about patent litigation and short interest. While the community remains divided, many retail traders are focused on the long-term potential of its AI data center power architecture despite recent price volatility.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

Community is laser-focused on Hyperliquid's potential US regulatory path after Trump signaled CFTC involvement, with Druckenmiller's disclosed stake and HYPE.X strength adding fuel. Traders are buzzing about a low-float short/gamma squeeze narrative into the upcoming earnings report, while CNBC attention keeps sentiment extremely bullish.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics is trending following an FDA notification of deficiencies in its Anaphylm application, which has paused labeling discussions but is not a final decision. While some investors fear a significant delay or rejection, many view the substantial stock pullback as an overreaction, anticipating that the issues are minor and will be resolved prior to the upcoming PDUFA date. The community is actively debating whether this signals a major setback or a strategic opportunity for eventual approval of the innovative needle-free allergy treatment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's Why You Should Add ACET Stock to Your Portfolio Now

Adicet Bio advances prula-cel in autoimmune diseases while pursuing new opportunities in prostate cancer and in vivo CAR-T.

Acadia Gets European Commission Nod for Daybu in Rett Syndrome

ACAD secures EC approval for Daybu, the first and only treatment approved in the EU for Rett syndrome, expanding its geographical reach.

Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?

ANIK's strong sales momentum and raised 2026 guidance bolster investor confidence, while Cingal and Hyalofast advance its pipeline.

TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette Syndrome

Teva's ecopipam secures FDA priority review for pediatric Tourette syndrome, potentially bringing the first new therapy in over a decade.

AC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for Pipeline

AC Immune reports favorable interim Phase 1 results for ACI-19764, an oral NLRP3 inhibitor showing strong safety and brain penetration.read more...

Reasons Why Investors Should Consider Betting on PGEN Stock 

Precigen's Papzimeos drives rapid revenue growth, while market exclusivity, global expansion and its pipeline add long-term potential.

RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos

Ultragenyx stock rises as Genglycos wins FDA's accelerated approval as the first treatment targeting the underlying cause of GSDIa, boosting its rare-disease portfolio.

Nuvectis Stock Surges Around 97% in 3 Months: Here's Why

NVCT's 97% three-month gain reflects optimism around its expanding pipeline, with NXP100 and NXP200 offering new value drivers.

ARGX Announces Positive Phase III Data on Vyvgart Hytrulo, Stock Up

argenx's shares jump 16% as Vyvgart Hytrulo delivered positive phase III ALKIVIA data, supporting its potential label expansion in autoimmune myositis.

UTHR Completes Phase III Tyvaso Study Enrollment for Expanded Label

United Therapeutics completes enrollment in its phase III study evaluating Tyvaso for an additional indication, PPF, with top-line results expected in the second half of 2027.

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eliseev on February 13, 2003 and is headquartered in Lausanne, Switzerland.

AC Immune SA

ACIU Stock Heads For Best Day In Over 10 Months On FDA Fast Track Nod For Parkinson’s Disease Therapy – Retail Sees ‘Breakout Soon’

Equity

Bullish Sentiment

Rallies more than 5%

Modest gain (0-5%)

Modest decline (0-5%)

Drops more than 5%

Nvidia ($NVDA) reports earnings Wednesday, August 26, with options markets pricing in a roughly 5-7% post-earnings move. How do you think Nvidia's stock reacts to earnings? Vote and explain your reasoning in the comments.

Nvidia ($NVDA) reports earnings Wednesday, with options markets pricing in a 5-7% move. How do you think the stock reacts?

Stocktwits

) reports earnings Wednesday, with options markets pricing in a 5-7% move. How do you think the stock reacts?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.20	--	--	N/A
Q2 '26	-$0.10	--	--	N/A
Q1 '26	-$0.19	-$0.19	3.87%	BEAT
Q4 '25	-$0.22	--	--	N/A
Q3 '25	-$0.23	-$0.16	28.13%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '26

Historical Earnings